Pemigatinib for Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse Cedex 9, France
Cancer+2 More
Pemigatinib - Drug
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a drug may help treat certain types of cancer.

See full description

Eligible Conditions

  • Cancer
  • Myeloproliferative Neoplasms (MPNs)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Pemigatinib will improve 1 primary outcome and 8 secondary outcomes in patients with Cancer. Measurement will happen over the course of From baseline through 30-35 days after end of treatment, up to 7 months per individual subject.

Month 24
The proportion of participants who achieve Complete Response (CR) based on response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement
Month 24
Duration of CR, defined as the time from first assessment of CR to the earlier of disease progression or death due to any cause
Duration of response, defined as the time from first assessment of CR or PR to the earlier of disease progression or death due to any cause
The proportion of subjects who achieve a complete cytogenetic response (CCyR) as assessed by local analysis and investigator evaluation
The proportion of subjects who achieve a partial cytogenetic response (PCyR) as assessed by local analysis and investigator evaluation
The proportion of subjects who achieve response, defined as a best response of CR or PR, as determined by investigator assessment according to the response criteria
Month 7
Safety and tolerability as assessed by frequency, duration, and severity of adverse events
Month 24
Overall survival
Month 24
Progression-free survival (PFS)

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

1 Treatment Group

Pemigatinib
1 of 1
Experimental Treatment

This trial requires 47 total participants across 1 different treatment group

This trial involves a single treatment. Pemigatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Pemigatinib
Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemigatinib
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: assessed at protocol-defined timepoints through end of study, up to approximately 24 months.
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly assessed at protocol-defined timepoints through end of study, up to approximately 24 months. for reporting.

Closest Location

Md Anderson Cancer Center - Houston, TX

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Cancer or one of the other 2 conditions listed above. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
People who have relapsed after stem cell transplantation or after other disease modifying therapy, or who are not current candidates for stem cell transplantation or other disease modifying therapies, can still participate in clinical trials. show original
The individual has a lymphoid or myeloid tumor with a rearrangement on chromosome 8p11 that is known to activate the FGFR1 gene, as determined by a standard cytogenetic evaluation performed locally show original
The following text is about subjects who have had a relapse or are refractory show original
The patient can expect to live for at least 12 weeks. show original
Satisfactory performance status in terms of ability to carry out normal activities of daily living. show original

Patient Q&A Section

How many people get cancer a year in the United States?

"A large percentage of people get some form of cancer at some point in time. Approximately 14.3% of men and 20.4% of women are found to have cancer at some point during their life. However, how many people get cancer a year in the United States is unknown. A good metric to use is to look at the average percentage of people with cancer per year per 10,000 in the general population. Then you just look at how many people get cancer during their lifetime. For example, there are approximately 2,622,000 people without cancer per year who do not get cancer." - Anonymous Online Contributor

Unverified Answer

What causes cancer?

"The risk of developing cancer is significantly increased if a patient has had cancer before, or their first-degree relative has had cancer or an organ-specific cancer. It has been shown that cancer cases were associated with cigarette smoking; excess risk did not seem to be related to age or alcohol consumption. In addition to the effects of environmental factors, individual susceptibility and the genetic predisposition to cancer are also strongly linked to increased risk. The risk of developing cancer is more important in smokers than non-smokers. The risk of developing cancer also appears to be increased by hereditary factors. Although cancers are not always benign, benign cancers have been linked to tobacco use. Some evidence exists linking schizophrenia with prostate cancer and thyroid cancer." - Anonymous Online Contributor

Unverified Answer

Can cancer be cured?

"There is no cure for cancer. If metastasis does not occur, then there is a possibility of curing the primary cancer. However, since metastasis still occurs, complete cure is not possible." - Anonymous Online Contributor

Unverified Answer

What is cancer?

"Most people in the developed world are concerned about cancer and some spend substantial time attempting to minimize possible risk. While cancer has always been a major public health issue, it is becoming obvious that such concern has led to a decrease in survival, to a marked increase in death as compared with the past. It would be wise to accept that cancer is inevitable and that we must strive to live. The aim of health care systems should be to make the best of every opportunity to prolong life, by preventing disease and illness through health care education and prevention of lifestyle factors. If we do not do this we will not have the resources or motivation that are necessary to live as long as we can without dying." - Anonymous Online Contributor

Unverified Answer

What are the signs of cancer?

"Symptoms have been used to diagnose cancer over a long period. Symptoms that indicate cancer are often poorly understood, and some may be of no use in diagnosis. It is likely that if symptoms do not correlate with the underlying disease, the patient will be reassured that they are a consequence rather than cause of their health problem. Further research should clarify the usefulness of many of those symptoms." - Anonymous Online Contributor

Unverified Answer

What are common treatments for cancer?

"Common treatments for cancer include some kind of surgery. The most common is chemotherapy (also known as "chemotherapy") that is a combination of drugs. Chemotherapy often involves a combination of several drugs: 5–10 different drugs (depending on type of cancer). In some cases the most common treatment is radiotherapy, a low-dose, high-dose, or a combination of treatment. Lastly, there is also a possibility of a combination of radiotherapy and an anti-cancer drug. Radiation therapy can be used in combination with radiation-resistant chemotherapy." - Anonymous Online Contributor

Unverified Answer

Is pemigatinib safe for people?

"Pemigatinib, used as the standard first line treatments for patients with advanced or metastatic EGFRvIII lung cancer, is generally well tolerated with no appreciable toxicities reported in this trial." - Anonymous Online Contributor

Unverified Answer

What is the latest research for cancer?

"The most recent published research is a mix of studies that have the most potential to affect current therapies and studies that have a great impact in the area of future prevention, diagnosis, and treatments. However, even the most recent reviews have not been conclusive, and some of the studies are far too small for conclusive conclusions." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets cancer?

"There is high heterogeneity in cancer staging and detection rates across countries and time; therefore, country-specific data are needed to make generalizations about the epidemiology of cancer in the world." - Anonymous Online Contributor

Unverified Answer

How does pemigatinib work?

"As an SMC-targeting, c-Met inhibitor with a novel mode that differs from first-generation c-Met inhibitors in that it only inhibits c-Met-inactivated cells, pemigatinib has significant efficacy in reducing tumour growth in multiple preclinical models (MDA- MB-231, T44, T47D and MCF-7), although it has not produced an objective response in the clinical setting. Despite significant pharmacodynamic, dose-increasing effects on other pathways, including AKT and epidermal growth factor receptor (EGFR), it remains an attractive pre-clinical anti-tumour agent." - Anonymous Online Contributor

Unverified Answer

What does pemigatinib usually treat?

"Dacarbazine is commonly used to treat soft tissue sarcomas. Pemigatinib can be an option in patients with unresectable or metastatic/high-risk soft tissue sarcomas whose tumours are positive for the chimeric receptors FLT3 and c-Met. The present findings warrant a multi-institution phase III trial of pemigatinib in combination with dacarbazine in patients with unresectable or borderline resectable soft tissue sarcomas bearing in situ or unresectable or metastatic, high-risk FLT3-ITD-positive (ITD mutation present) or c-MET-positive tumour." - Anonymous Online Contributor

Unverified Answer

How serious can cancer be?

"When patients are informed that their cancer will be completely incurable, they tend to place less importance on physical characteristics, especially age. When patients are made aware of other treatments other than complete cure, they tend to place more value on health-related factors. The importance placed on non-physical factors by cancer patients and on physical factors by their family caregivers may be a key factor for the perception of personal control, as well as the type and amount of treatment that cancer patients receive." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.